{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T17:39:42Z","timestamp":1790876382125,"version":"4.1.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2010,7,1]],"date-time":"2010-07-01T00:00:00Z","timestamp":1277942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,7,1]],"date-time":"2010-07-01T00:00:00Z","timestamp":1277942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","surgonc.theclinics.com","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Surgical Oncology Clinics of North America"],"published-print":{"date-parts":[[2010,7]]},"DOI":"10.1016\/j.soc.2010.03.005","type":"journal-article","created":{"date-parts":[[2010,7,2]],"date-time":"2010-07-02T04:39:56Z","timestamp":1278045596000},"page":"463-473","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Breast Cancer Chemoprevention: Progress and Controversy"],"prefix":"10.1016","volume":"19","author":[{"given":"D. Lawrence","family":"Wickerham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.soc.2010.03.005_bib1","first-page":"225","article-title":"Cancer statistics, 2009","volume":"59","author":"Jemal","year":"2009","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.soc.2010.03.005_bib2","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1056\/NEJM199901143400201","article-title":"Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer","volume":"340","author":"Hartmann","year":"1999","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.soc.2010.03.005_bib3","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1126\/science.278.5340.1073","article-title":"Recent advances in chemoprevention of cancer","volume":"278","author":"Hong","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.soc.2010.03.005_bib4","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/S0140-6736(97)11423-4","article-title":"Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group","volume":"351","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.soc.2010.03.005_bib5","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1093\/jnci\/90.18.1371","article-title":"Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study","volume":"90","author":"Fisher","year":"1998","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.soc.2010.03.005_bib6","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1093\/jnci\/dji372","article-title":"Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study","volume":"97","author":"Fisher","year":"2005","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.soc.2010.03.005_bib7","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1001\/jama.286.18.2251","article-title":"Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP P-1) breast cancer prevention trial","volume":"286","author":"King","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.soc.2010.03.005_bib8","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1016\/S0140-6736(00)03258-X","article-title":"Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group","volume":"356","author":"Narod","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.soc.2010.03.005_bib9","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0140-6736(02)09962-2","article-title":"First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial","volume":"360","author":"Cuzick","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.soc.2010.03.005_bib10","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1093\/jnci\/djk049","article-title":"Long-term results of tamoxifen prophylaxis for breast cancer\u201396-month follow-up of the randomized IBIS-I trial","volume":"99","author":"Cuzick","year":"2007","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.soc.2010.03.005_bib11","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/S0140-6736(98)85012-5","article-title":"Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial","volume":"352","author":"Powles","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.soc.2010.03.005_bib12","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1093\/jnci\/djk050","article-title":"Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial","volume":"99","author":"Powles","year":"2007","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.soc.2010.03.005_bib13","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1093\/jnci\/95.2.160","article-title":"Italian randomized trial among women with hysterectomy: tamoxifen and hormone-dependent breast cancer in high-risk women","volume":"95","author":"Veronesi","year":"2003","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.soc.2010.03.005_bib14","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/S0140-6736(03)12342-2","article-title":"Overview of the main outcomes in breast-cancer prevention trials","volume":"361","author":"Cuzick","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.soc.2010.03.005_bib15","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1001\/jama.281.23.2189","article-title":"The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation","volume":"281","author":"Cummings","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.soc.2010.03.005_bib16","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1093\/jnci\/djh319","article-title":"Continuing Outcomes Relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene","volume":"96","author":"Martino","year":"2004","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.soc.2010.03.005_bib17","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1001\/jama.295.23.joc60074","article-title":"Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial","volume":"295","author":"Vogel","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.soc.2010.03.005_bib18","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1158\/0008-5472.SABCS-11","article-title":"Effects of 5 years of treatment with lasofoxifene on incidence of breast cancer in older women","volume":"69","author":"LaCroix","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.soc.2010.03.005_bib19","doi-asserted-by":"crossref","unstructured":"Powles T, Diem S, Wickerham L, et\u00a0al. Effects of arzoxifene on breast cancer incidence in postmenopausal women with osteoporosis or with low bone mass [abstract 51]. San Antonio Breast Cancer Symposium. San Antonio (TX), December 11, 2009, General Session IV.","DOI":"10.1158\/0008-5472.SABCS-09-51"},{"key":"10.1016\/j.soc.2010.03.005_bib20","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1200\/JCO.2001.19.3.881","article-title":"Aromatase inhibitors in the treatment and prevention of breast cancer","volume":"19","author":"Goss","year":"2001","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.soc.2010.03.005_bib21","author":"Th\u00fcerlimann"},{"issue":"Suppl 1","key":"10.1016\/j.soc.2010.03.005_bib22","first-page":"S1","article-title":"Benefits of switching postmenopausal women with hormone-sensitive early breast cancer to anastrozole after 2 years adjuvant tamoxifen: combined results from 3,123 women enrolled in the ABCSG Trial 8 and the ARNO 95 Trial [abstract 2]","volume":"88","author":"Jakesz","year":"2004","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.soc.2010.03.005_bib23","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1056\/NEJMoa032312","article-title":"A\u00a0randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer","volume":"349","author":"Goss","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.soc.2010.03.005_bib24","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1056\/NEJMoa040331","article-title":"A\u00a0randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer","volume":"350","author":"Coombes","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.soc.2010.03.005_bib25","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1016\/S0140-6736(02)09088-8","article-title":"Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial","volume":"359","author":"Baum","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.soc.2010.03.005_bib26","doi-asserted-by":"crossref","first-page":"3235","DOI":"10.1200\/JCO.2008.20.5179","article-title":"American Society of Clinical Oncology Clinical Practice Guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction","volume":"27","author":"Visvanathan","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.soc.2010.03.005_bib27","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1200\/JCO.1999.17.6.1939","article-title":"American Society of Clinical Oncology technology assessment on breast cancer risk reduction strategies: tamoxifen and raloxifene","volume":"17","author":"Chlebowski","year":"1999","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.soc.2010.03.005_bib28","doi-asserted-by":"crossref","first-page":"3328","DOI":"10.1200\/JCO.2002.06.029","article-title":"American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition","volume":"20","author":"Chelbowski","year":"2002","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Surgical Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1055320710000244?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1055320710000244?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T11:55:55Z","timestamp":1760961355000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1055320710000244"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,7]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,7]]}},"alternative-id":["S1055320710000244"],"URL":"https:\/\/doi.org\/10.1016\/j.soc.2010.03.005","relation":{},"ISSN":["1055-3207"],"issn-type":[{"value":"1055-3207","type":"print"}],"subject":[],"published":{"date-parts":[[2010,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Breast Cancer Chemoprevention: Progress and Controversy","name":"articletitle","label":"Article Title"},{"value":"Surgical Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.soc.2010.03.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}